STOCK TITAN

Timber Pharmaceuticals Inc - TMBR STOCK NEWS

Welcome to our dedicated news page for Timber Pharmaceuticals (Ticker: TMBR), a resource for investors and traders seeking the latest updates and insights on Timber Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Timber Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Timber Pharmaceuticals's position in the market.

Rhea-AI Summary
Timber Pharmaceuticals, Inc. (TMBR) faces delisting from NYSE American due to voluntary bankruptcy petitions, with common stock expected to trade on the OTC market under the symbol TMBRQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.97%
Tags
none
-
Rhea-AI Summary
Timber Pharmaceuticals, Inc. (NYSE American: TMBR) announced that all 'first day' motions related to the Company's voluntary Chapter 11 petitions for reorganization were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. The Court approved an initial $3.0 million in interim funding pursuant to a debtor-in-possession financing facility. The Company will continue its ongoing Phase 3 ASCEND study for TMB-001, while pursuing a court-supervised process for the sale of its assets to a 'stalking horse' bidder affiliated with LEO. However, the NYSE Regulation has notified Timber about delisting proceedings and non-compliance with continued listing standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Summary
Timber Pharmaceuticals regains compliance with NYSE American listing standards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Timber Pharmaceuticals to be acquired by LEO US Holding for up to $36 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
110.56%
Tags
-
Rhea-AI Summary
Timber Pharmaceuticals, Inc. has received a letter from NYSE American stating that the company is not in compliance with the listing standards due to stockholders' deficit and losses. The company's shares will continue to be listed and traded on the NYSE American, but with an added designation of '.BC'. Timber Pharmaceuticals is required to submit a plan of compliance by July 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Timber Pharmaceuticals announces interim pharmacokinetic results from Phase 3 ASCEND study, indicating minimal systemic absorption of isotretinoin in patients with congenital ichthyosis. Full results to be presented at the Society for Pediatric Dermatology’s Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.37%
Tags
Timber Pharmaceuticals Inc

NYSE:TMBR

TMBR Rankings

TMBR Stock Data

1.18M
2.79M
1.12%
7.79%
0.23%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Menlo Park

About TMBR

timber pharmaceuticals llc, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. the company was founded in 2019 and is based in woodcliff lake, new jersey.